glp 1 drugs and ulcerative colitis The alleviating effect mechanism of GLP-1 on Frontiers | GLP-1 receptor agonists

The combined impact exceeds what either pathway accomplishes alone

Accessed 2025 Apr 25

Treatment recommendations are individualized and based on safety, appropriateness, and clinical judgment

Approved by the FDA in 2015, Tresiba is classified as an ultra-long-acting basal insulin analog designed to provide consistent, background insulin coverage for up to 42 hours after a single injection

To identify new users based on a 1-year washout period, only those with 1-year continuous registration before cohort entry were included

While the evidence base for some of these approaches is developing, clinicians play an incredibly important role by providing structured monitoring, reinforcing sustainable lifestyle practices, and tailoring support to individual needs